Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli’s potential in wet AMD and forecasting $1.5 billion peak sales.
Latest Ratings for OCUL
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | JMP Securities | Maintains | Market Outperform | |
| Nov 2021 | JMP Securities | Maintains | Market Outperform | |
| Oct 2021 | HC Wainwright & Co. | Maintains | Buy |
